Examination of the Role of Religious and Psychosocial Factors in HIV Medication Adherence Rates
- 519 Downloads
Optimal adherence to antiretroviral therapy (ART) is associated with favorable HIV outcomes, including higher CD4 cell counts, HIV virus suppression and a lower risk of HIV transmission. However, only 25% of people living with HIV/AIDS (PLWH) in the USA are virally suppressed. Sub-optimal adherence (<90–95%) contributes to antiretroviral resistance and worse medical outcomes, including more rapid progression to AIDS and death. Psychosocial factors and religion/spirituality (R/S) have a significant impact on ART adherence, but the findings are mixed. The purpose of this study was to examine religious and psychosocial correlates and predictors of ≥90% ART adherence in PLWH. A cross-sectional study was conducted with a sample of 292 outpatient PLWH in the Southeastern USA. Participants completed computerized surveys. The mean ART adherence percentage was 80.9% and only about half reported ≥90% adherence. There were statistically significant differences in ART adherence rates based on age, depressive symptom status and frequency of religious attendance and prayer. Praying at least once a day was significantly associated with ≥90% ART adherence (OR = 2.26, 95% CI [1.06–4.79], p < 0.05). Social support satisfaction was also significantly associated with ART adherence (OR = 1.52, 95% CI [1.11–2.08], p < 0.05) and energy/fatigue/vitality (OR = 1.03, 95% CI [1.00–1.05], p < 0.05).
KeywordsHIV/AIDS Medication adherence Religion Spirituality Antiretroviral therapy
This research was supported by a grant from The John Templeton Foundation supporting Dr. George Dalmida’s postdoctoral fellowship in Religion and Health research at Duke University.
Compliance with Ethical Standards
Conflict of interest
The authors declare that there are no conflicts of interest.
All procedures performed in this study were in accordance with the ethical standards of the University and University Medical Center Institutional Research Boards.
Informed consent was obtained from all individual participants included in the study.
- Bader, A., Kremer, H., Erlich-Trungenberger, I., Rojas, R., Lohmann, M., Deobald, O., et al. (2006). An adherence typology: Coping, quality of life, and physical symptoms of people living with HIV/AIDS and their adherence to antiretroviral treatment. Medical Science Monitor, 12(12), CR493–CR500.PubMedGoogle Scholar
- Castro, K. G., Ward, J. W., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., et al. (1993). 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Clinical Infectious Diseases, 17(4), 802–810.CrossRefGoogle Scholar
- Centers for Disease Control and Prevention. (2012). CDC Fact Sheet. HIV in the United States: The Stages of Care. Retrieved from www.cdc.gov/hiv/pdf/research_mmp_stagesofcare.pdf.
- Eaton, J. W., Johnson, L. F., Salomon, J. A., Barnighausen, T., Bendavid, E., Bershteyn, A., et al. (2012). HIV treatment as prevention: Systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Medicine, 9(7), e1001245. doi: 10.1371/journal.pmed.1001245.CrossRefPubMedPubMedCentralGoogle Scholar
- Finocchario-Kessler, S., Catley, D., Berkley-Patton, J., Gerkovich, M., Williams, K., Banderas, J., et al. (2011). Baseline predictors of ninety percent or higher antiretroviral therapy adherence in a diverse urban sample: The role of patient autonomy and fatalistic religious beliefs. AIDS Patient Care STDS, 25(2), 103–111.CrossRefPubMedPubMedCentralGoogle Scholar
- Gardner, E. M., Sharma, S., Peng, G., Hullsiek, K. H., Burman, W. J., Macarthur, R. D., et al. (2008). Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. Aids, 22(1), 75–82. doi: 10.1097/QAD.0b013e3282f366ff.CrossRefPubMedPubMedCentralGoogle Scholar
- Gonzalez, J. S., Psaros, C., Batchelder, A., Applebaum, A., Newville, H., & Safren, S. A. (2011b). Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment. Annals of Behavioral Medicine, 42(1), 120–126. doi: 10.1007/s12160-011-9268-y.CrossRefPubMedPubMedCentralGoogle Scholar
- Harding, R., Lampe, F. C., Norwood, S., Date, H. L., Clucas, C., Fisher, M., et al. (2010). Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sexually Transmitted Infections, 86(7), 520–524. doi: 10.1136/sti.2009.038505.CrossRefPubMedGoogle Scholar
- Holstad, M. M., Foster, V., Diiorio, C., McCarty, F., & Teplinskiy, I. (2010). An examination of the psychometric properties of the Antiretroviral General Adherence Scale (AGAS) in two samples of HIV-infected individuals. Journal of the Association of Nurses in AIDS Care, 21(2), 162–172. doi: 10.1016/j.jana.2009.08.002.CrossRefPubMedGoogle Scholar
- Institute, Fetzer. (1999). Multidimensional measurement of religiousness/spirituality for use in health research: A report of the Fetzer Institute/National Institute on Aging Working Group. Kalamazoo, MI: John E. Fetzer Institute.Google Scholar
- Ironson, G., Stuetzle, R., & Fletcher, M. A. (2006). An increase in religiousness/spirituality occurs after HIV diagnosis and predicts slower disease progression over 4 years in people with HIV. Journal of General Internal Medicine, 21(Suppl 5), S62–S68. doi: 10.1111/j.1525-1497.2006.00648.x.CrossRefPubMedPubMedCentralGoogle Scholar
- Liu, H., Miller, L. G., Hays, R. D., Golin, C. E., Wu, T., Wenger, N. S., et al. (2006). Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. Journal of Acquired Immune Deficiency Syndromes, 41(3), 315–322. doi: 10.1097/01.qai.0000197071.77482.6e.CrossRefPubMedGoogle Scholar
- Montaner, J. S., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., et al. (1998). A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA, 279(12), 930–937.CrossRefPubMedGoogle Scholar
- Radloff, L. S., & Locke, B. Z. (1986). The community mental health assessment survey and CES-D scale. In M. M. Weissman & J. K. Meyers (Eds.), Community surveys of psychiatric disorders (pp. 177–187). New Brunswick, NJ: Rutgers University Press.Google Scholar
- Stansell, J., Holtzer, C., Mayer, S., DeGuzman, D., Hamel, E., & Lapins, D. (2001). Factors affecting treatment outcomes in a medication event monitoring system. Paper presented at the Retroviruses and Opportunistic Infections, Chicago, Ill.Google Scholar
- Thielman, N. M., Ostermann, J., Whetten, K., Whetten, R., Itemba, D., Maro, V., et al. (2014). Reduced adherence to antiretroviral therapy among HIV-Infected Tanzanians seeking cure from the Loliondo Healer. JAIDS Journal of Acquired Immune Deficiency Syndromes, 65(3), e104–e109.CrossRefPubMedGoogle Scholar
- Vedhara, K., Schifitto, G., & McDermott, M. (1999). Disease progression in HIV-positive women with moderate to severe immunosuppression: The role of depression. Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. Behavioral Medicine, 25(1), 43–47. doi: 10.1080/08964289909596738.CrossRefPubMedGoogle Scholar